Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selma Ugurel

Showing results (121-130 of 265) with videos related to

Pageof 27
Sort By:
European Radiology|May 1, 2025
Adverse effects of systemic advanced melanoma therapies-do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?Marcel Alexander Drews, Alexander Baumgarten, Sebastian Zensen, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 14, 2021
Carl Maximilian Thielmann, Selma Ugurel, Elisabeth Livingstone, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsAnne Zaremba, Alexander M M Eggermont, Caroline Robert, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 24, 2021
Metastatic pigmented epithelioid melanocytoma in a 7-year-old femaleCarl Maximilian Thielmann, Selma Ugurel, Elisabeth Livingstone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2022
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective studyMartin Salzmann, Johannes Pawlowski, Carmen Loquai, et al.
Proteomics. Clinical Applications|December 8, 2010
Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approachBalwir Matharoo-Ball, Lucy Ratcliffe, Lee Lancashire, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2021
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF<sup>V600</sup> mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trialLisa Zimmer, Elisabeth Livingstone, Angela Krackhardt, et al.
Anti-Cancer Drugs|June 5, 2003
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility studyClaudia Pföhler, Ian A Cree, Selma Ugurel, et al.
Frontiers in Immunology|April 3, 2023
COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center studyGeorg Christian Lodde, Frederik Krefting, Jan-Malte Placke, et al.
Oncotarget|January 23, 2016
SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanomaChristoph Willmes, Rajiv Kumar, Jürgen C Becker, et al.
Pageof 27

Showing results (121-130 of 265) with videos related to

Sort By:
Pageof 27
European Radiology|May 1, 2025
Adverse effects of systemic advanced melanoma therapies-do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?Marcel Alexander Drews, Alexander Baumgarten, Sebastian Zensen, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 14, 2021
Carl Maximilian Thielmann, Selma Ugurel, Elisabeth Livingstone, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsAnne Zaremba, Alexander M M Eggermont, Caroline Robert, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 24, 2021
Metastatic pigmented epithelioid melanocytoma in a 7-year-old femaleCarl Maximilian Thielmann, Selma Ugurel, Elisabeth Livingstone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2022
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective studyMartin Salzmann, Johannes Pawlowski, Carmen Loquai, et al.
Proteomics. Clinical Applications|December 8, 2010
Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approachBalwir Matharoo-Ball, Lucy Ratcliffe, Lee Lancashire, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2021
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF<sup>V600</sup> mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trialLisa Zimmer, Elisabeth Livingstone, Angela Krackhardt, et al.
Anti-Cancer Drugs|June 5, 2003
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility studyClaudia Pföhler, Ian A Cree, Selma Ugurel, et al.
Frontiers in Immunology|April 3, 2023
COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center studyGeorg Christian Lodde, Frederik Krefting, Jan-Malte Placke, et al.
Oncotarget|January 23, 2016
SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanomaChristoph Willmes, Rajiv Kumar, Jürgen C Becker, et al.
Pageof 27